VivaChek
VivaChek is a Hangzhou-based Chinese POCT manufacturer founded in 2013 that designs electrochemical biosensor blood glucose meters, multi-parameter glucose/ketone/uric acid analyzers, rapid infectious disease tests, and the VivaChek Cloud chronic disease management platform, serving hospitals, consumers, and government health agencies in 140+ countries.
- Company typePrivate
- Founded2013
- HeadquartersHangzhou, China
- Headcount501–1,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What VivaChek does
VivaChek (杭州微策生物技术股份有限公司) is a privately-held Chinese POCT (Point-of-Care Testing) manufacturer founded in August 2013 in Hangzhou's Linping District, with a workforce of 501–1,000 employees. The company designs, manufactures, and sells electrochemical biosensor-based diagnostic devices — its foundation is a proprietary single-layer 8-electrode test strip using FAD-GDH dehydrogenase chemistry, with clinical-grade interference resistance and EN ISO 15197:2015 accuracy. The product portfolio spans blood glucose meters (830/740/790 4G/Pro/NB-IoT 5G series), multi-parameter glucose/ketone/uric acid analyzers, lactate and uric acid single-parameter meters, veterinary meters (VQpet/VetSight), colloidal gold rapid tests (FOB, COVID-19/flu A/B combo, Strep A, HbA1c), hair drug testing analyzers, dry fluorescence immunoassay systems (VIM2000/VIM3000) with associated biomarker kits, and the VivaChek Cloud chronic disease management platform. NB-IoT/4G/Bluetooth/WiFi connectivity is integrated across the meter line for automatic data upload to the cloud platform.
The commercial model is hardware-anchored with a recurring consumables (test strips) tail, organized around four customer segments: (1) domestic tier-2-and-above hospitals and provincial health commissions (e.g., Qinghai chronic disease program) via field sales and direct distributor relationships; (2) individual consumers/home users via pharmacy chains, Tmall, and WeChat mini-programs under the VivaChek Ino, 好糖, and VQpet sub-brands; (3) international distributors and government health agencies (NHS prescribing directory, Sri Lanka and Moldova Ministries of Health) across 140+ countries; and (4) law enforcement/government for hair drug testing. Wholly-owned overseas subsidiaries in the United States, Hong Kong, India, and Singapore anchor the export business, complemented by Greylynx (辉瓴生物) for infectious disease rapid tests. Pricing is contact-based and not publicly disclosed; revenue mix is dominated by hardware shipments and consumable reorders rather than disclosed SaaS subscriptions, although the cloud platform supports recurring data service revenue.
The company holds US FDA 510(k) clearance for six VivaChek Ino glucose meter models (Dec 2018) and VivaChek Link Plus 4G (Dec 2023); EU IVDR Class C CE certification (Jan 2024); MDSAP five-country certification (Apr 2021); and additional NMPA, MHRA, TGA, and HSA approvals. As of December 2024, it holds 263 registered trademarks and 209 granted patents (30 invention patents). Strategic partners include Shenzhen Gaotejia Investment Group (2016), Kailian Medical Technology (2020 — insulin pump integration), and Guangdong Lifesense Medical Electronics (2023 — channel and product development). National recognitions include Specialized, Refined, and Innovative 'Little Giant' (2023) and Zhejiang Provincial Enterprise Technology Center (Jan 2026). Revenue is not publicly disclosed.
VivaChek firmographics
Firmographics- Name
- VivaChek
- Legal name
- 杭州微策生物技术股份有限公司
- Website
- https://vivachek.com.cn
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- VivaChek is a Hangzhou-based Chinese POCT manufacturer founded in 2013 that designs electrochemical biosensor blood glucose meters, multi-parameter glucose/ketone/uric acid analyzers, rapid infectious disease tests, and the VivaChek Cloud chronic disease management platform, serving hospitals, consumers, and government health agencies in 140+ countries.
- Ownership category
- akta.pro rank
VivaChek industry classification
Industry- Product category
- Point-of-Care Diagnostic Devices (In-Vitro Diagnostics)
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate) (HLAHAOAB)
- akta.pro secondary industries
- Home-Use & OTC Rapid Self-Tests (Consumer POCT kits) (HLAHAOAK), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)
Keywords
Where VivaChek is headquartered
LocationHeadquarters
- HQ city
- Hangzhou
- HQ country
- China
- HQ region
- Asia
Offices6 records
Markets served
VivaChek business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- POCT Diagnostic Instruments and Consumables: 微策生物 generates revenue primarily from the sale of POCT diagnostic instruments (blood glucose meters, multi-analyte analyzers) and their corresponding consumable test strips. Products are sold globally through distributors, hospital channels, pharmacy chains, and e-commerce platforms.
- Cloud-based Data Services: 微策云 platform enables remote patient monitoring and data management, supporting the sale of connected IoT devices (5G/4G blood glucose meters) that drive ongoing data service revenue through cloud platform subscriptions.
Go-to-market motion3 records
Distribution channels6 records
Marketing channels6 records
VivaChek product offering
Product offeringCore offering
VivaChek designs, manufactures, and sells POCT (point-of-care testing) diagnostic instruments and consumables, centered on blood glucose meters and test strips but extending to multi-parameter (glucose/ketone/uric acid) analyzers, lactate analyzers, immunofluorescence analyzers, and colloidal gold rapid test kits (FOB, COVID-19, Strep A, hair drug testing). Products are sold globally to hospitals, pharmacies, consumers, and government health programs, with connected devices feeding data into the VivaChek Cloud chronic disease management platform.
Product overview
VivaChek (微策生物) is a POCT (Point-of-Care Testing) company offering a comprehensive product ecosystem centered on blood glucose monitoring and multi-parameter metabolic detection. The portfolio includes: (1) Core glucose meters (830/840/740/790 4G/NB-IoT 5G series), (2) Multi-parameter analyzers for glucose/ketone/uric acid (including Pro version with HIS/LIS integration), (3) Lactate analyzers for sports health, (4) Veterinary blood glucose/ketone meters (VQpet/VetSight), (5) Colloidal gold rapid tests including fecal occult blood (FOB), COVID-19/flu combo, and Strep A, (6) Fluorescent immunoassay (VIM2000/VIM3000) system with 10+ biomarker test kits, (7) Hair drug detection series, and (8) 微策云 cloud platform enabling real-time data sync and remote monitoring. The company positions itself as a 'smart POCT provider' with products spanning chronic disease management (diabetes, hyperuricemia, ketone monitoring), gastrointestinal early screening, sports health, veterinary diagnostics, and drug testing.
Differentiator
Problem solved
Functional benefit
Brands
- 好糖 (HaoTang): Consumer-oriented blood glucose meter brand featuring the 好糖易可III blood glucose meter. Products use single strip packaging for enhanced safety and stability, satisfying ISO15197 standards.
- 亲宠 (QinChong / VQpet)
- VivaDiag
Products and services
- VivaChek 3-in-1 Blood Glucose/Ketone/Uric Acid Analyzer (微策® 血糖/血酮/尿酸分析仪) Multi-function analyzer that simultaneously detects blood glucose, blood ketone, and uric acid using single-layer 8-electrode FAD-GDH technology with strong anti-interference performance, requiring only 0.5 microliter blood sample and supporting Bluetooth/4G data transmission.
- VivaChek Pro Blood Glucose/Ketone/Uric Acid Analyzer (微策® Pro血糖/血酮/尿酸分析仪) Pro-version multi-function analyzer that syncs glucose/ketone/uric acid test data in 3 seconds with direct HIS/LIS integration, designed for hospital inpatient use with cross-department collaborative management.
- VivaChek 4G Blood Glucose/Ketone/Uric Acid Analyzer (微策® 4G血糖/血酮/尿酸分析仪)
Quantifiable outcome
- Self-monitoring of blood glucose has been clinically proven to increase blood glucose compliance rate by 54.2%
- +3 more outcomes
Companies that use VivaChek
Customer profileNamed customers8 records
Segments5 records
Ideal customer profiles5 records
VivaChek technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability4 records
Feature5 records
VivaChek partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- 广东乐心医疗电子股份有限公司 (Lifesense Medical Electronics, Stock Code: 300562)core微策生物 and Lifesense Medical signed a strategic cooperation agreement to jointly develop the blood glucose monitoring market. The partnership integrates both companies' core R&D capabilities and channel resources to enhance blood glucose monitoring product sales channels and extend medical services. Both companies share a common vision for the blood glucose monitoring market's broad prospects, combining 微策's POCT technology advantage with Lifesense's intelligent health device capabilities and international sales network.
- 凯联医疗科技（上海）有限公司 (Kailian Medical Technology)core微策生物 and Kailian Medical entered a strategic partnership to develop a semi-closed-loop smart blood glucose management solution. The partnership combines 微策's Bluetooth blood glucose monitoring system with Kailian's smart insulin pump (乐泵) to enable data integration between monitoring and treatment, reducing闭环 insulin pump device algorithm complexity and safety risks. This was the first strategic collaboration between an insulin pump and blood glucose meter manufacturer in China.
Scale indicators7 records
Recent moves11 records
Expansion highlights6 records
VivaChek competitors and assessment
Company assessmentDirect peers
- Sinocare (三诺生物): Leading Chinese blood glucose monitoring and POCT company, listed on Shenzhen Stock Exchange (300298). Most direct domestic competitor to VivaChek with overlapping hospital and consumer BGM product lines, IVD focus, and Chinese hospital channel presence.
- Acon Laboratories: US-based diagnostics company with strong BGM and rapid test portfolio. Comparable in offering consumer and clinical BGM, IVD rapid tests, and serving international distributors across multiple continents.
- i-SENS: Korean BGM and continuous glucose monitoring company with global distribution including Europe and Asia. Direct competitor in electrochemical blood glucose strips, hospital-grade meters, and multi-parameter analyzers.
- Ascensia Diabetes Care: Switzerland-based BGM specialist (Contour portfolio) spun out from Bayer. Direct competitor in consumer and pharmacy-channel blood glucose monitoring globally, with comparable regulatory footprint in IVDR/FDA.
- Lifesense Medical (乐心医疗): Chinese-listed intelligent health devices company (SZSE: 300562) and VivaChek's strategic partner. Directly comparable in connected BGM and remote monitoring focus, with overlapping IoT-enabled device approach and chronic disease management platform strategy.
Broad incumbents
- Abbott Diabetes Care: Global BGM and continuous glucose monitoring leader (FreeStyle Libre). Comparable in connected diabetes devices and international distribution; sets competitive pressure for IoT-enabled glucose monitoring that VivaChek is pursuing in China.
- Mindray (迈瑞医疗): Largest Chinese medical device company with strong IVD and patient monitoring presence. Comparable hospital channel reach in tiered Chinese hospitals and overlapping POCT/in-vitro diagnostic product lines.
- Roche Diabetes Care: Global leader in blood glucose monitoring under Accu-Chek brand. Sets the technology and regulatory benchmark for the BGM category and competes with VivaChek in hospital BGM and self-monitoring globally.
- Yuyue Medical (鱼跃医疗): Major Chinese medical device manufacturer with broad product portfolio including BGM, blood pressure monitors, and home healthcare. Comparable in hospital channel and consumer BGM but operates across much wider medical device categories at significantly larger scale.
Regional players
- ARKRAY: Japanese clinical diagnostics and BGM company. Comparable in hospital-grade glucose monitoring and urine analysis devices, with strong presence in Asia-Pacific hospital channel.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
VivaChek social profiles
Digital presenceVivaChek compliance and trust
Trust signalCompliance13 records
VivaChek financial estimates
Financial estimateRevenue estimate
Valuation estimate
VivaChek leadership team
Management profileNumber of profiles
Profiles4 records
VivaChek subsidiaries and ownership
Company hierarchySubsidiaries4 records
VivaChek funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VivaChek M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VivaChek
What does VivaChek do?
VivaChek designs, manufactures, and sells POCT (point-of-care testing) diagnostic instruments and consumables, centered on blood glucose meters and test strips but extending to multi-parameter (glucose/ketone/uric acid) analyzers, lactate analyzers, immunofluorescence analyzers, and colloidal gold rapid test kits (FOB, COVID-19, Strep A, hair drug testing). Products are sold globally to hospitals, pharmacies, consumers, and government health programs, with connected devices feeding data into the VivaChek Cloud chronic disease management platform.
Is VivaChek a public or private company?
VivaChek is a private company. It is classified as venture growth investor backed and is currently operating.
When was VivaChek founded?
VivaChek was founded in 2013. It employs 501 to 1,000 people.
Where is VivaChek based?
VivaChek is headquartered in Hangzhou, China, in the Asia region.
How does VivaChek make money?
Two revenue lines are on record. POCT Diagnostic Instruments and Consumables are the primary driver. The others are cloud-based Data Services.
Who are VivaChek's main competitors?
Direct peers on record are Sinocare (三诺生物), Acon Laboratories, i-SENS, Ascensia Diabetes Care and Lifesense Medical (乐心医疗). Broad incumbents are Abbott Diabetes Care, Mindray (迈瑞医疗), Roche Diabetes Care and Yuyue Medical (鱼跃医疗). ARKRAY is listed as a regional player.
Does VivaChek have an API?
No public API is recorded for VivaChek.
What industry is VivaChek in?
VivaChek's product category is Point-of-Care Diagnostic Devices (In-Vitro Diagnostics). Its primary akta.pro industry code is HLAHAOAB, Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate), with a secondary code of HLAHAOAK, Home-Use & OTC Rapid Self-Tests (Consumer POCT kits). Its NAICS code is 325413 and its SIC code is 3841.